1. Home
  2. OXM vs PRTA Comparison

OXM vs PRTA Comparison

Compare OXM & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oxford Industries Inc.

OXM

Oxford Industries Inc.

HOLD

Current Price

$26.34

Market Cap

543.0M

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$8.68

Market Cap

458.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OXM
PRTA
Founded
1942
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
543.0M
458.4M
IPO Year
1994
2013

Fundamental Metrics

Financial Performance
Metric
OXM
PRTA
Price
$26.34
$8.68
Analyst Decision
Hold
Buy
Analyst Count
4
9
Target Price
$38.00
$19.00
AVG Volume (30 Days)
481.0K
325.2K
Earning Date
06-10-2026
05-07-2026
Dividend Yield
6.80%
N/A
EPS Growth
N/A
N/A
EPS
4.25
0.26
Revenue
$1,477,834,000.00
$814,000.00
Revenue This Year
$2.85
$1,111.38
Revenue Next Year
$2.63
N/A
P/E Ratio
$6.61
$34.58
Revenue Growth
N/A
N/A
52 Week Low
$27.85
$7.73
52 Week High
$49.58
$11.80

Technical Indicators

Market Signals
Indicator
OXM
PRTA
Relative Strength Index (RSI) 24.33 49.87
Support Level N/A $8.12
Resistance Level $42.57 $9.36
Average True Range (ATR) 1.41 0.31
MACD -0.39 -0.04
Stochastic Oscillator 0.00 44.31

Price Performance

Historical Comparison
OXM
PRTA

About OXM Oxford Industries Inc.

Oxford Industries Inc is an apparel manufacturing company that designs, sources, markets, and distributes products under the brand name Tommy Bahama, and Lilly Pulitzer. Tommy Bahama designs, sources, markets, and distributes men's and women's sportswear and related products. Lilly Pulitzer designs, sources, markets, and distributes upscale collections of women's and women's dresses, sportswear, and related products. The company's business is organized as: Tommy Bahama, Lilly Pulitzer, Johnny Was and Emerging Brands reportable segments. Geographically, the company operates in United States as well as Internationally.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: